Compare · NVO vs QNTM
NVO vs QNTM
Side-by-side comparison of Novo Nordisk A/S (NVO) and Quantum Biopharma Ltd. (QNTM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QNTM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 7067.7x QNTM ($25.9M).
- Over the past year, NVO is down 45.7% and QNTM is down 73.1% - NVO leads by 27.4 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 7 for QNTM).
- NVO has more recent analyst coverage (25 ratings vs 0 for QNTM).
- Company
- Novo Nordisk A/S
- Quantum Biopharma Ltd.
- Price
- $41.01-4.51%
- $4.05-6.57%
- Market cap
- $183.15B
- $25.9M
- 1M return
- -10.44%
- -19.40%
- 1Y return
- -45.66%
- -73.11%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest QNTM
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
- Quantum BioPharma Provides Corporate Update
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
- SEC Form 6-K filed by Quantum Biopharma Ltd.